• 1
    Del Zoppo GJ, Eliasziw M. New options in anticoagulation for atrial fibrillation. N Engl J Med 2011; 365: 9523.
  • 2
    Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major haemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 268996.
  • 3
    Stangier J, Rathgen K, Stäle H, Mazur D. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292303.
  • 4
    Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-center study. Clin Pharmacokinet 2010; 49: 25968.
  • 5
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener H-C, Joyner CD, Wallentin L, the RE-LY Steering Committee and Investigors. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 113951.
  • 6
    Eikelboom JW, Walentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Ailings M, Kaatz S, Hohnloser SH, Diener H-C, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation. An analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Circulation 2011; 123: 236372.
  • 7
    Moia M, Mannucci PM. Letter to the editor. N Engl J Med 2009; 361: 2672.
  • 8
    MHRA. Dabigatran (Pradaxa): risk of serious haemorrhage – need for renal function testing. Drug Saf Update 2011; 5: A2.
  • 9
    CHMP post-authorisation summary of opinion for Pradaxa. EMA/337053/2012. Available at (last accessed 2 July 2012).
  • 10
    Chin PKL, Vella-Brincat JWA, Barclay ML, Begg EJ. Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles? Br J Clin Pharmacol 2012; 74: 73440.
  • 11
    Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Haertter S, Staab A. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE_LY trial. J Thromb Haemost 2011; 9: 216875.
  • 12
    Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47: 4759.
  • 13
    Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23: 13843.